Abcam, ab265680, Human PSMD10 (Gankyrin) knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
PSMD10 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PSMD10, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Gankyrin or PSMD10 is an oncogene with a molecular mass of around 25 kDa. It is a small heat-stable protein predominantly expressed in the cytoplasm of various tissues. The protein contains multiple ankyrin repeats that facilitate protein-protein interactions. It is overexpressed in many types of cancer tissues including liver breast and lung cancer. Gankyrin interacts with various cell cycle regulators and serves as an adaptor molecule enhancing its significance in cellular processes.
Biological function summary
Gankyrin enhances the degradation of the retinoblastoma protein (pRb) as part of the 26S proteasome complex. This function disrupts normal cell cycle control promoting cell proliferation. Gankyrin binds directly to the cyclin-dependent kinase 4 (CDK4) and MDM2 which regulate pRb and p53 tumor suppressor pathways. Overexpression of Gankyrin contributes to cellular transformation and oncogenesis by regulating cell cycle progression and apoptosis.
Pathways
Gankyrin participates actively in p53 and ubiquitin-proteasome pathways. The protein facilitates ubiquitination and degradation of key regulators including p53 and pRb altering the stability of these proteins. Gankyrin interacts with proteins like MDM2 and HDAC1 influencing their roles in tumor development through these pathways. Its presence in these pathways contributes to unchecked cell growth by evading normal tumor suppressor mechanisms.
Gankyrin has strong associations with cancer particularly in hepatocellular carcinoma and colorectal cancer. In these cancers it influences tumor progression and metastasis by altering the functions of proteins within the p53 pathway such as MDM2 and pRb. In hepatocellular carcinoma increased Gankyrin activity correlates with poor prognosis and aggressive tumor behavior while in colorectal cancer its interaction with these proteins may contribute to chemotherapy resistance.